Pulmokine is a biopharmaceutical company developing a novel class of kinase inhibitors for pulmonary related diseases. Its first program, currently in clinical development, is an inhaled small molecule inhibitor of PDGFR for the treatment of pulmonary arterial hypertension (PAH).

Gossamer Bio (NASDAQ:GOSS) has licensed the PAH program (GB002) and will manage and fund the development through regulatory approval.